Strand Therapeutics

📍 Boston, United States🗓 Founded 2017👥 121 employees💰 Last funded Aug 2025
Strand was founded by biological engineers working together at the Massachusetts Institute of Technology (MIT). Building on the idea of creating smart therapies capable of making sophisticated decisions, they sought to apply this concept to the emerging field of mRNA therapeutics. This area was previously untapped by traditional synthetic biology, leading us to build our very own mRNA programming language, creating the world’s first platform for mRNA smart therapies. Strand’s mRNA programming technology promises to make mRNA therapies safer and more effective by programming the location, timing, and intensity of therapeutic protein expression inside a patient’s body via mRNA-encoded logic circuits. These circuits have the ability to implement cell-type specific expressions by sensing and classifying the unique mRNA expression signatures of cells and control the dosage of protein expression through responses to exogenously administered small molecules.
7
Total investors
3
Early stage
1
Mid stage
3
Late stage
2017
Founded
Investor geography2 countries
United States
6
Japan
1
Investor activity2019–2025 · investors recorded per year
201932022120253
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Strand Therapeutics?
Strand Therapeutics has 7 investors on record on gritt.io, including 3 early-stage backers, 1 mid-stage and 3 late-stage investors.
When did Strand Therapeutics last raise funding?
The most recent investment in Strand Therapeutics recorded on gritt.io was in August 2025.
When was Strand Therapeutics founded?
Strand Therapeutics was founded in 2017.
What industry is Strand Therapeutics in?
Strand Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Strand Therapeutics based?
Strand Therapeutics is headquartered in Boston, United States.